Tempus AI (NASDAQ:TEM) CEO Ryan Fukushima Sells 41,095 Shares

Tempus AI, Inc. (NASDAQ:TEM) CEO Ryan Fukushima sold 41,095 shares of the company’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $49.61, for a total transaction of $2,038,722.95. Following the transaction, the chief executive officer owned 562,463 shares in the company, valued at $27,903,789.43. This represents a 6.81% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Ryan Fukushima also recently made the following trade(s):

• On Friday, August 7th, Ryan Fukushima sold 20,000 shares of Tempus AI stock. The shares were sold at an average price of $50.04, for a total transaction of $1,000,800.00.
• On Monday, August 3rd, Ryan Fukushima sold 23,818 shares of Tempus AI stock. The stock was sold at an average price of $46.19, for a total transaction of $1,100,153.42.
• On Wednesday, July 8th, Ryan Fukushima sold 33,284 shares of Tempus AI stock. The shares were sold at an average price of $57.39, for a total transaction of $1,910,168.76.
• On Monday, July 6th, Ryan Fukushima sold 10,000 shares of Tempus AI stock. The stock was sold at an average price of $60.00, for a total transaction of $600,000.00.

Tempus AI Price Performance

Shares of TEM opened at $66.65 on Friday. The firm has a market cap of $12.03 billion, a PE ratio of -46.28 and a beta of 3.58. The company has a current ratio of 3.30, a quick ratio of 3.16 and a debt-to-equity ratio of 3.06. The firm has a fifty day simple moving average of $52.44 and a two-hundred day simple moving average of $51.21. Tempus AI, Inc. has a 1-year low of $40.77 and a 1-year high of $104.32.

Tempus AI (NASDAQ:TEM) last released its quarterly earnings results on Thursday, July 30th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.10. Tempus AI had a negative return on equity of 50.28% and a negative net margin of 17.77%.The firm had revenue of $382.49 million for the quarter, compared to the consensus estimate of $379.69 million. During the same period last year, the business posted ($0.22) EPS. The company’s revenue for the quarter was up 21.6% on a year-over-year basis. On average, equities analysts anticipate that Tempus AI, Inc. will post -1.38 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on TEM. Guggenheim boosted their price target on Tempus AI from $60.00 to $65.00 and gave the company a “buy” rating in a research note on Thursday, July 16th. Freedom Capital upgraded shares of Tempus AI to a “hold” rating in a research note on Tuesday, June 30th. TD Cowen restated a “buy” rating on shares of Tempus AI in a research report on Wednesday, July 15th. Wolfe Research assumed coverage on shares of Tempus AI in a research report on Tuesday, June 2nd. They set a “peer perform” rating for the company. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $75.00 target price on shares of Tempus AI in a report on Friday, July 31st. Nine equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, Tempus AI presently has an average rating of “Hold” and a consensus target price of $65.69.

Institutional Trading of Tempus AI

Several hedge funds have recently bought and sold shares of TEM. Victory Capital Management Inc. raised its stake in shares of Tempus AI by 1.5% in the third quarter. Victory Capital Management Inc. now owns 11,078 shares of the company’s stock worth $894,000 after buying an additional 162 shares during the period. Truist Financial Corp lifted its position in shares of Tempus AI by 5.8% during the 4th quarter. Truist Financial Corp now owns 3,532 shares of the company’s stock valued at $209,000 after buying an additional 194 shares in the last quarter. Farther Finance Advisors LLC grew its stake in shares of Tempus AI by 3.5% during the 4th quarter. Farther Finance Advisors LLC now owns 6,390 shares of the company’s stock valued at $377,000 after acquiring an additional 219 shares during the period. SeaCrest Wealth Management LLC grew its stake in shares of Tempus AI by 3.7% during the 3rd quarter. SeaCrest Wealth Management LLC now owns 6,488 shares of the company’s stock valued at $524,000 after acquiring an additional 229 shares during the period. Finally, Geneos Wealth Management Inc. increased its holdings in Tempus AI by 29.4% in the 4th quarter. Geneos Wealth Management Inc. now owns 1,100 shares of the company’s stock worth $65,000 after acquiring an additional 250 shares in the last quarter. Institutional investors own 24.22% of the company’s stock.

Key Tempus AI News

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: BTIG raised its price target to $80 from $70 and maintained a “Buy” rating, implying roughly 20% upside from the referenced price. The upgrade provided a direct catalyst for investor buying. BTIG raises Tempus AI price target
• Positive Sentiment: Investor attention is focusing on Tempus AI’s approximately $1.5 billion stock-based agreement to acquire Personalis. The deal is increasingly viewed as strategically valuable because Personalis’ genomic data and cancer-testing capabilities could strengthen Tempus’ precision-medicine and drug-development platform. Tempus AI biotech deal attracts investor attention
• Positive Sentiment: Moderna’s reported cancer-vaccine progress, alongside developments involving Merck, has encouraged investors to believe Tempus’ Personalis acquisition could benefit from increased demand for genomic data and personalized cancer treatment. The connection is indirect, but it has improved sentiment around Tempus’ strategic positioning. Tempus AI stock rises after Merck-Moderna cancer vaccine breakthrough
• Positive Sentiment: The rally was accompanied by unusually high options activity, with investors buying 40,671 call contracts—about 57% above average daily call volume—signaling increased bullish speculation and potentially reinforcing upward momentum.
• Neutral Sentiment: Technical factors also contributed: TEM moved above key moving averages, while coverage characterized the move as a possible short squeeze. These conditions can accelerate gains but may also increase volatility. Tempus AI stock technical rally

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.